AI Science Tracker

Lund University

1 discovery from 2023

Discoveries

MASAI: AI-assisted mammography screening in a randomized trial

In the initial analysis of 80,033 women, AI-assisted screening detected 244 cancers versus 203 with standard double reading and reduced the reading workload by 44%. A Lund update on January 30, 2026, after more than two years and about 106,000 women, reports higher sensitivity without more false positives. The comparison is in a Swedish setting; it does not demonstrate reduced mortality.

Technology: AI for mammogram triage and marking

Publication: Publication status unspecified in annotation · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Not reported
  • Test type: prospective or independent check
  • Tested: A prospective randomized single-site trial compared AI-supported screening (about 40,003 women) with standard double reading (about 40,030 women), measuring cancers detected, false positives and radiologist workload.
  • Still unknown: The Lund article states limits: single site, no mortality outcomes, and the main analysis awaits two-year follow-up; the January 2026 update could not be verified on the page read.
  • AI role: AI flagged higher-risk mammography exams for two physicians or marked suspicious findings for a single reader.

Evidence sources: https://www.lu.se/artikel/ai-stodd-modell-saker-mammografiscreening

The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.